Syntimmune is leveraging a deep understanding of FcRn biology to develop transformative therapies for patients with autoimmune diseases. The company has advanced rapidly into the clinic with its lead investigational candidate, a monoclonal antibody that rapidly inhibits pathogenic IgG and has potential as a pipeline-in-a-product in dermatology, rheumatology, hematology, neurology and nephrology.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.